Journal
CLINICAL EPIGENETICS
Volume 14, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13148-022-01255-1
Keywords
Epstein-Barr virus; DNA methylation; Epigenetics; Post-transplant lymphoproliferative disease
Categories
Funding
- Programme de Recherche Translationnelle en Cancerologie (PRT-K) (INCa-DGOS)
Ask authors/readers for more resources
A new molecular assay (methyl-qPCR) was designed to distinguish methylated versus unmethylated Epstein-Barr virus (EBV) genomes. This method showed potential for distinguishing latent and lytic EBV genomes in transplant recipients, aiding in treatment decisions.
Epstein-Barr virus DNA viral load is used as a surrogate marker to start Rituximab in transplant recipients at risk of developing PTLD. However, an elevated EBV DNAemia does not discriminate lymphoproliferation and replication. We designed a new molecular assay (methyl-qPCR) to distinguish methylated versus unmethylated viral genomes. In blood, viral genomes were highly methylated in EBV primary infections, PTLD and 4/5 transplant recipients with high viral load. The only patient with under-methylated EBV genomes did not respond to rituximab. Methyl-qPCR is a convenient method to discriminate between latent and lytic EBV genomes and could be useful in treatment decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
